OpenEvidence is leveraging a partnership with Memorial Sloan Kettering Cancer Center to bolster its oncology capabilities, adding trusted genomic interpretation expertise to the AI platform already used by millions of clinicians.
Through the partnership, the company will integrate OncoKB, MSK's precision oncology knowledge base, directly into its workflows for broader use by providers outside of MSK.
The partnership brings precision oncology decision support to clinicians nationwide and deepens OpenEvidence's push into cancer care as the company already directly integrates the foundational frameworks of cancer treatment into its medical search engine.
Through its latest partnership with MSK, OpenEvidence users gain access to expert-curated interpretations of cancer genomic alterations alongside patient-specific context and peer-reviewed evidence, helping clinicians make more informed treatment decisions, according to OpenEvidence executives.
【MORE】